Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum (Q46681078)
Jump to navigation
Jump to search
scientific article published in September 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum |
scientific article published in September 2005 |
Statements
1 reference
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum (English)
1 reference
Laurence Collette
1 reference
Kevin J Carroll
1 reference
Don Newling
1 reference
Tom Morris
1 reference
Fritz H Schröder
1 reference
European Organisation for Research and Treatment of Cancer
1 reference
Limburgs Universitair Centrum
1 reference
AstraZeneca Pharmaceuticals
1 reference
1 September 2005
1 reference
1 reference
23
1 reference
25
1 reference
6139-6148
1 reference
Identifiers
1 reference
1 reference